Presentation is loading. Please wait.

Presentation is loading. Please wait.

The tp53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non–small cell lung.

Published byRasmus Eggen Modified over 5 years ago

Similar presentations

Presentation on theme: "The tp53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non–small cell lung."— Presentation transcript:

1 The tp53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non–small cell lung cancer  Daniela Kandioler-Eckersberger, MD a, S. Kappel, PhD, MDa, M. Mittlböck, PhDc, G. Dekan, MDd, C. Ludwig, PhDa, E. Janschek, MDa, R. Pirker, MDb, E. Wolner, MDa, F. Eckersberger, MDa  The Journal of Thoracic and Cardiovascular Surgery  Volume 117, Issue 4, Pages (April 1999) DOI: /S (99) Copyright © 1999 Mosby, Inc. Terms and Conditions

2 Fig. 1 Kaplan-Meier estimation of survival in patients with and without TP53 mutations. A significant survival advantage was found for patients with normal TP53 genotype. Patients with normal TP53 genotype were found to correspond to those with treatment response. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (99) ) Copyright © 1999 Mosby, Inc. Terms and Conditions

3 Fig. 2 Sequencing analysis showing part of exon 7 of the TP53 gene from normal and tumor DNA of patient 855 (with NSCLC unresponsive to cisplatin-based therapy). Tumor sequence shows mutation in codon 248, a cytosine to thymine transition (arrow). The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (99) ) Copyright © 1999 Mosby, Inc. Terms and Conditions

Download ppt "The tp53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non–small cell lung."

Similar presentations

Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis Alessandro Marra, MD, PhD, Ludger Hillejan, MD,

Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis Alessandro Marra, MD, PhD, Ludger Hillejan, MD,
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma  Hideyuki Imoto, MD, Toshihiro.

Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma  Hideyuki Imoto, MD, Toshihiro.
Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,
Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment  William C Nugent, MD, Mark T Edney, BA, Paul G Hammerness, BA, Bradley.

Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment  William C Nugent, MD, Mark T Edney, BA, Paul G Hammerness, BA, Bradley.
Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L
Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M
Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,
Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 

Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 
Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.
Detection of circulating tumor cells in patients with non–small cell lung cancer undergoing lobectomy by video-assisted thoracic surgery: A potential.

Detection of circulating tumor cells in patients with non–small cell lung cancer undergoing lobectomy by video-assisted thoracic surgery: A potential.
Circulating tumor DNA: Solid data from liquid biopsies

Circulating tumor DNA: Solid data from liquid biopsies
Survival after resection of synchronous non–small cell lung cancer

Survival after resection of synchronous non–small cell lung cancer
Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E

Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E
Jean Paul A. Couetil, MDa, Didier P

Jean Paul A. Couetil, MDa, Didier P
Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer  Masatsugu Hamaji, MD, Mark S. Allen,

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer  Masatsugu Hamaji, MD, Mark S. Allen,
Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer 

Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer 

Similar presentations

Ads by Google